Prostate cancer is particularly suited to precision radiation because the prostate is a relatively small organ that can be targeted from multiple directions while attempting to limit exposure to surrounding tissues. SBRT delivers a high biological dose in a small number of treatment sessions, using advanced image guidance and treatment planning to account for organ motion and anatomy. In NRG-GU005, patients assigned to the SBRT group received 36.25 Gy in five fractions. Patients in the comparison group received MH-IMRT, delivered either as 70 Gy in 28 fractions or 60 Gy in 20 fractions. While conventional radiation may require several weeks of daily visits, SBRT can be completed in approximately one week, a difference that could reduce travel, treatment costs, time away from work, and the logistical burden on patients and families.

The trial enrolled 698 evaluable participants with intermediate-risk disease and was designed around two co-primary endpoints: disease-free survival and patient-reported health-related quality of life. Researchers assessed quality of life with the 26-item Expanded Prostate Cancer Index Composite, commonly known as EPIC-26. The instrument measures treatment effects in several domains, including bowel function, urinary irritative and obstructive symptoms, urinary incontinence, sexual function, and hormonal symptoms. For the primary quality-of-life analysis, investigators focused on whether patients experienced a minimally clinically important difference, or MCID, in bowel health or urinary irritative and obstructive symptoms. An MCID is intended to represent a change noticeable and meaningful to patients rather than merely a statistically measurable difference in a score.

At two years, 34.9 percent of men treated with SBRT experienced an MCID in the bowel domain, compared with 43.8 percent of those treated with MH-IMRT. The difference was statistically significant, with a p value of 0.034, indicating that the probability of observing such a result by chance alone was relatively low under the study’s statistical assumptions. Longitudinal analyses, which examine changes over time rather than relying on a single follow-up point, also associated SBRT with improved bowel-domain scores. The use of rectal spacers was linked to better bowel outcomes as well. These devices are placed between the prostate and rectum to increase physical separation, potentially reducing the amount of radiation delivered to the rectal wall during treatment.

The bowel result did not extend to the trial’s urinary co-primary endpoint. An MCID in urinary irritative or obstructive symptoms occurred in 33.7 percent of patients in the SBRT arm and 34.7 percent in the MH-IMRT arm. The difference was not statistically significant, with a p value of 0.68. Urinary irritation and obstruction can result from radiation-related inflammation or changes in the prostate and urethra, and the similar rates in both groups suggest that delivering radiation in five fractions did not substantially alter this aspect of recovery compared with moderately shortened IMRT. Because both quality-of-life domains had to meet the prespecified criteria for the co-primary endpoint to be considered positive, the urinary result meant that the trial did not fulfill its overall health-related quality-of-life objective.

The study also did not establish a disease-control advantage for SBRT. An interim analysis crossed the trial’s futility boundary for superiority, meaning that the accumulating data made it unlikely that SBRT would ultimately prove superior to MH-IMRT for disease-free survival. According to the investigators, this conclusion was driven solely by a higher number of biochemical failures in the SBRT group. Biochemical failure is generally identified through rising prostate-specific antigen, or PSA, after treatment. PSA is a sensitive marker of prostate activity, but a biochemical recurrence does not always immediately correspond to visible metastatic disease or a decline in overall survival. Longer follow-up remains important because prostate cancer can recur many years after initial treatment, and early PSA patterns may not fully predict long-term clinical outcomes.

The investigators reported additional differences in patient-reported genitourinary outcomes. SBRT was associated with lower incontinence-related quality of life, indicating a less favorable experience in that specific domain, while it was also associated with improved maintenance of erectile dysfunction compared with MH-IMRT. These findings illustrate why radiation comparisons cannot be reduced to a single measure of toxicity. A treatment may perform better for bowel symptoms while producing different trade-offs in urinary continence or sexual function. The prostate, rectum, bladder, urethra, and neurovascular structures occupy a tightly packed region of the pelvis, and radiation dose, fraction size, baseline function, anatomy, technical planning, and the use of protective devices can all influence late effects.

The NRG-GU005 results add to evidence from other randomized studies examining shorter prostate radiation schedules. The PACE-B trial previously showed that SBRT was non-inferior to conventionally fractionated or moderately hypofractionated radiation for disease control in an appropriate patient population. NRG-GU005 was designed to ask a more demanding question: whether SBRT could deliver superior disease-free survival while also producing a clinically meaningful improvement in selected quality-of-life outcomes. The answer was no under the trial’s predefined criteria. Nevertheless, the bowel findings may be relevant to shared decision-making, particularly for patients who value fewer treatment visits and are concerned about gastrointestinal effects. Physicians will still need to weigh these potential advantages against urinary and sexual side effects, baseline symptoms, prostate anatomy, rectal spacer availability, and the uncertainty surrounding long-term biochemical control.

“This major clinical trial teaches us not only about state-of-the-art radiation technology, but also about the biology of radiation effects on prostate cancer and normal organs responsible for basic human functions,” Mitchell Machtay of Penn State, NRG Oncology’s group deputy chair and chief scientific officer, said in a statement. Rodney J. Ellis of the University of South Florida, the study’s lead author, said the trial was not positive overall but noted that SBRT produced a favorable outcome in the EPIC-26 bowel domain and not in the urinary irritative or obstructive domain. He emphasized that additional follow-up is needed to clarify longer-term outcomes. The trial was supported by the National Cancer Institute through the National Clinical Trials Network and conducted by NRG Oncology, a research group formed from the legacy Radiation Therapy Oncology Group, National Surgical Adjuvant Breast and Bowel Project, and Gynecologic Oncology Group programs. For now, the findings suggest that SBRT is a time-saving alternative with a distinct quality-of-life profile, not a universally superior replacement for MH-IMRT.

Subject of Research: SBRT versus moderately hypofractionated IMRT for localized intermediate-risk prostate cancer

Article Title: Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial

News Publication Date: August 13, 2026

Web References: https://pubmed.ncbi.nlm.nih.gov/42593775/

References: Ellis RJ, Pugh SL, Yu JB, et al. “Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.” Journal of the American Medical Association. 2026. doi:10.1001/jama.2026.12627.

Keywords: prostate cancer, SBRT, stereotactic body radiation therapy, IMRT, hypofractionated radiotherapy, NRG-GU005, radiation oncology, quality of life, EPIC-26, disease-free survival, PSA, rectal spacers

Radiation-induced rib fractures represent a growing concern in thoracic radiotherapy due to the increasing use of hypofractionated regimens, where higher doses per fraction are delivered to reduce treatment times and potentially improve tumor control. While hypofractionation has demonstrated therapeutic benefits, it also amplifies the biological impact on non-target tissues. Particularly with proton and carbon-ion therapies, whose physical dose distributions differ substantially from conventional photon beams, the characterization and mitigation of toxicities such as RIRFs remain inadequately elucidated. This study pioneers an in-depth examination of these risks specifically within the context of passive-scattering proton beam therapy.

The research team conducted a meticulous retrospective analysis of 85 patients afflicted with stage I NSCLC, all treated with a consistent proton dose of 66–70 Gy (relative biological effectiveness, RBE) administered in 10 fractions. A stringent follow-up period of no less than 36 months was enforced to capture late-onset rib fractures, which may often remain asymptomatic and thus undetected without thorough imaging surveillance. This extended observation window is vital, as radiation-induced bone injuries can manifest long after therapy completion, obscuring direct causal links in shorter studies.

Rib fractures were detected primarily via high-resolution chest computed tomography (CT) scans, independent of the presence or absence of symptomatic thoracic pain. This approach underscores the importance of imaging-based surveillance in revealing subclinical complications that could have significant clinical implications. The ability to correlate rib fracture occurrences with precise dose-volume histogram (DVH) parameters derived from retrospective treatment plan analysis enabled a granular understanding of radiation dose distribution effects on distinct rib segments.

Statistical scrutiny encompassed both Kaplan–Meier survival analyses for fracture-free intervals and Cox proportional hazards models to identify robust predictors of RIRFs. Notably, out of 85 patients, 55 (64.7%) experienced at least one rib fracture, culminating in a staggering total of 116 fractured ribs. The cumulative incidence rose steeply over time, with 36.5% and 52.9% of patients sustaining fractures by 2 and 3 years post-treatment, respectively, highlighting this complication’s prevalence and clinical significance.

One of the pivotal findings lies in the dose-response relationship at the level of individual ribs. By focusing on ribs exposed to at least 50 Gy (RBE), the analysis included 224 rib units, encompassing all fractured instances. Higher maximum doses delivered to small volumes within a rib showed a clear association with fracture risk, establishing dosimetry as a critical determinant. The spatial location of the maximum dose also emerged as significant — fractures were more likely when the high dose area corresponded with structurally vulnerable rib regions.

Beyond pure dosimetric factors, the study innovatively incorporated patient-specific skeletal considerations into the risk assessment paradigm. Bone mineral density (BMD), a surrogate marker of overall bone strength, was inversely correlated with fracture incidence. This finding aligns with known biological principles that weaker bones are more susceptible to radiation damage and subsequent mechanical failure. Furthermore, specific anatomical rib segments, such as the first rib, proved particularly vulnerable, potentially attributable to unique biomechanical stresses and vascular supply patterns.

An intriguing clinical variable that modulated fracture risk was the systemic use of corticosteroids. These agents, while therapeutically valuable for many conditions, may exacerbate bone fragility through inhibition of osteoblast activity and promotion of bone resorption. Their identification as an independent risk factor stresses the necessity for multidisciplinary consideration when managing patients undergoing radiotherapy.

The median latency period from treatment to fracture was approximately 23.5 months, with occurrences spanning from as early as five months to as late as over five years post-therapy. This wide temporal range emphasizes the need for long-term, possibly lifelong, surveillance of patients receiving proton therapy to promptly identify and manage late skeletal toxicities.

This study’s findings deliver crucial insights that could guide future radiotherapy planning and patient management. Incorporating detailed dose constraints to safeguard rib integrity, especially limiting high-dose “hot spots” in vulnerable anatomical locations, may reduce RIRF risk. Simultaneously, pre-treatment assessment of bone health, potentially including dual-energy X-ray absorptiometry (DXA) scans to quantify BMD, could stratify patients based on susceptibility, enabling tailored protective strategies.

Moreover, the interplay of corticosteroid use with radiation effects on bone underscores a pressing need for heightened vigilance in patients requiring such medications concurrent with or following radiotherapy. Inter-disciplinary collaboration with endocrinologists or bone metabolism specialists might be prudent to optimize bone-preserving interventions and monitor fracture risk.

These revelations also prompt a broader reflection on radiation toxicity paradigms in proton therapy. Despite protons’ theoretical advantage in sparing healthy tissues due to their characteristic Bragg peak, localized dose escalations remain a double-edged sword, harboring potential for unintended collateral damage. The complex biomechanical milieu of ribs, with varying cortical thickness, marrow composition, and loading patterns, demands an individualized approach in dose sculpting and risk evaluation.

The study’s retrospective design, though informative, invites further prospective investigations with larger cohorts and incorporation of advanced imaging biomarkers to refine predictive models. Future research might also explore protective agents or rehabilitative modalities that could mitigate or ameliorate radiation-induced bone injuries.

Ultimately, this seminal work reverberates beyond NSCLC radiotherapy, encouraging cancer care teams to integrate skeletal health considerations when devising treatment plans involving hypofractionated regimens and charged-particle therapies. Enhancing patient quality of life through minimization of painful, debilitating rib fractures represents a pivotal frontier in the ongoing evolution of oncologic precision medicine.

In summary, the determination of multifaceted risk factors—including dosimetric parameters, anatomical nuances, bone mineral density, and corticosteroid use—opens avenues for more comprehensive and personalized radiation oncology strategies. These insights aim to optimize the therapeutic index of proton beam therapy, maximizing tumor eradication while safeguarding patients from the insidious sequelae of skeletal complications.

As proton therapy continues to gain traction worldwide, integrating these findings into clinical protocols promises not only enhanced safety but also a deeper understanding of radiobiological interactions at the bone-tissue interface. This foundational knowledge lays the groundwork for future innovations that could revolutionize how radiation-induced toxicities are predicted, prevented, and managed in thoracic oncology.

By bridging clinical observations with rigorous dosimetric analysis, this investigation exemplifies the power of multidisciplinary research in advancing the frontiers of radiation medicine. As we stride toward increasingly precise and patient-tailored cancer treatments, acknowledging and addressing the subtle yet impactful risks such as radiation-induced rib fractures will be paramount in delivering truly holistic care.

Subject of Research: Risk factors for radiation-induced rib fractures following proton beam therapy in stage I non-small cell lung cancer.

Article Title: Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study.

Article References:
Kondo, N., Yoshiura, T., Kakinohana, Y. et al. Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study. BMC Cancer 25, 682 (2025). https://doi.org/10.1186/s12885-025-14047-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14047-6